{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T15:11:46Z","timestamp":1648912306305},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T00:00:00Z","timestamp":1536278400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00108-018-0491-5","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T09:49:28Z","timestamp":1536313768000},"page":"86-89","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pektangin\u00f6se Beschwerden bei einem 47-j\u00e4hrigen athletischen Patienten mit Psoriasis vulgaris"],"prefix":"10.1007","volume":"60","author":[{"given":"S.","family":"Braumann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. K.","family":"Peitsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Michels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,7]]},"reference":[{"key":"491_CR1","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/ibd.20894","volume":"15","author":"C Abraham","year":"2009","unstructured":"Abraham C, Cho J (2009) Interleukin-23\/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis 15:1090\u20131100","journal-title":"Inflamm Bowel Dis"},{"key":"491_CR2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1684\/ejd.2009.0644","volume":"19","author":"E Altobelli","year":"2009","unstructured":"Altobelli E, Petrocelli R, Maccarone M et al (2009) Risk factors of hypertension, diabetes and obesity in Italian psoriasis patients: a\u00a0survey on socio-demographic characteristics, smoking habits and alcohol consumption. Eur J Dermatol 19:252\u2013256","journal-title":"Eur J Dermatol"},{"issue":"4","key":"491_CR3","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1600-0625.2011.01261.x","volume":"20","author":"WH Boehncke","year":"2011","unstructured":"Boehncke WH, Boehncke S, Tobin AM, Kirby B (2011) The \u2018psoriatic march\u2019: a\u00a0concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 20(4):303\u2013307","journal-title":"Exp Dermatol"},{"key":"491_CR4","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.jaad.2017.06.028","volume":"77","author":"A Egeberg","year":"2017","unstructured":"Egeberg A, Skov L, Joshi AA et\u00a0al (2017) The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. J\u00a0Am Acad Dermatol 77:650\u2013656","journal-title":"J Am Acad Dermatol"},{"issue":"14","key":"491_CR5","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","volume":"296","author":"JM Gelfand","year":"2006","unstructured":"Gelfand JM, Neimann AL, Shin DB et\u00a0al (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296(14):1735\u20131741","journal-title":"JAMA"},{"key":"491_CR6","first-page":"1493","volume":"143","author":"JM Gelfand","year":"2007","unstructured":"Gelfand JM, Troxel AB, Lewis JD et al (2007) The risk of mortality in patients with psoriasis: results from a\u00a0population-based study. Arch Dermatol 143:1493\u20131499","journal-title":"Arch Dermatol"},{"issue":"6","key":"491_CR7","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jaad.2008.01.006","volume":"58","author":"AB Kimball","year":"2008","unstructured":"Kimball AB, Gladman D, Gelfand JM et\u00a0al (2008) National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J\u00a0Am Acad Dermatol 58(6):1031\u20131042","journal-title":"J Am Acad Dermatol"},{"key":"491_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1161\/CIRCULATIONAHA.116.026859","volume":"136","author":"JB Lerman","year":"2017","unstructured":"Lerman JB, Joshi AA, Chaturvedi A et al (2017) Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a\u00a0prospective observational study. Circulation 136:263\u2013276","journal-title":"Circulation"},{"key":"491_CR9","volume-title":"S3-Leitlinie zur Therapie der Psoriasis vulgaris. Update 2017","author":"A Nast","year":"2017","unstructured":"Nast A, Amelunxen L, Augustin M et al (2017) S3-Leitlinie zur Therapie der Psoriasis vulgaris. Update 2017. http:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/013-001l_S3_Therapie_Psoriasis-vulgaris_2017-12.pdf"},{"key":"491_CR10","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s12016-016-8560-9","volume":"51","author":"ZS Yang","year":"2016","unstructured":"Yang ZS, Lin NN, Li L, Li Y (2016) The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis. Clin Rev Allergy Immunol 51:240\u2013247","journal-title":"Clin. Rev. Allergy. Immunol."}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-018-0491-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0491-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0491-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,9]],"date-time":"2020-11-09T05:02:26Z","timestamp":1604898146000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-018-0491-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,7]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["491"],"URL":"https:\/\/doi.org\/10.1007\/s00108-018-0491-5","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,7]]},"assertion":[{"value":"7 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"W.K.\u00a0Peitsch f\u00fchrte klinische Studien f\u00fcr AbbVie, Boehringer-Ingelheim, Eli Lilly, Janssen-Cilag, Merck, Novartis, Pfizer und UCB Pharma durch; nahm an \u201eadvisory boards\u201c von AbbVie, Eli Lilly, LEO Pharma, MSD und Novartis teil; bekam Vortragshonorare von ALK-Abell\u00f3, AbbVie, Janssen-Cilag, MSD, Novartis und Roche und erhielt Unterst\u00fctzung f\u00fcr Fortbildungen von AbbVie, Actelion, ALK-Abell\u00f3, Allergika, Alma Lasers, ARC Lasers, Asclepion, Beiersdorf, BMS, Celgene, Dermapharm, Dermasence, Eli Lilly, Galderma, GSK, IGEA, Interlac, Janssen-Cilag, L\u2019Or\u00e9al, La Roche-Posay, LEO Pharma, Medac, Merck, MSD, Novartis, Pierre Fabre, P&M Cosmetics, Pfizer, Roche und Stiefel. S.\u00a0Braumann, R.\u00a0Pfister und G.\u00a0Michels geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren. Alle Patienten, die \u00fcber Bildmaterial oder anderweitige Angaben innerhalb des Manuskriptes zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}